About 54,590 results

ALLMedicine™ Ovarian Cancer Center

Research & Reviews  17,299 results

Effect of Apatinib Plus Pegylated Liposomal Doxorubicin vs Pegylated Liposomal Doxorubi...
JAMA Oncology; Wang T, Tang J et. al.

Jul 1st, 2022 - There are substantial unmet therapeutic needs in patients with platinum-resistant recurrent ovarian cancer (PROC), and novel therapeutic strategies should be explored. To evaluate the efficacy and safety of treatment with apatinib (a vascular endo...

The Comprehensive Analysis of Interferon-Related Prognostic Signature with regard to Im...
Disease Markers; An Y, Duan H

Jul 1st, 2022 - Interferon plays an important role in immune response of ovarian cancer. However, the expression pattern of interferon in ovarian cancer remains unclear. This study is aimed at exploring the expression profile of interferon-relate genes and constr...

Downregulation of DNMT3A Attenuates the Warburg Effect, Proliferation, and Invasion via...
Technology in Cancer Research & Treatment; Lu J, Zhen S et. al.

Jul 1st, 2022 - Background: Ovarian cancer is a highly malignant gynecological cancer. Aerobic glycolysis is one of the features of cancer cell metabolism. Studying the molecular modulation of the Warburg effect in ovarian cancer is significantly valuable for und...

Advances of Exosomal microRNAs and Proteins in Ovarian Cancer Diagnosis, Prognosis, and...
Current Molecular Medicine; Qin T, Chen F et. al.

Jul 1st, 2022 - Late diagnosis, postoperative recurrence, and chemotherapy resistance are the main causes of the high mortality rate of ovarian cancer (OC). Understanding the molecular mechanisms in the pathogenesis and progression of OC may contribute to discove...

MIR503HG impeded ovarian cancer progression by interacting with SPI1 and preventing TME...
Aging Tian J, Yang L et. al.

Jul 1st, 2022 - MIR503 host gene (MIR503HG) acts as an important tumor suppressor in many human cancers, but its role and regulatory mechanism in ovarian cancer need to be further studied. In this study, lower expressed MIR503HG was observed in ovarian tumor tiss...

see more →

Guidelines  54 results

Risk-Reducing Salpingo-Oophorectomy and the Use of Hormone Replacement Therapy Below th...
BJOG : an International Journal of Obstetrics and Gynaeco... Manchanda R, Gaba F et. al.

Oct 22nd, 2021 - This paper deals with the use of hormone replacement therapy (HRT) after the removal of fallopian tubes and ovaries to prevent ovarian cancer in premenopausal high risk women. Some women have an alteration in their genetic code, which makes them m...

Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.
Journal of the National Comprehensive Cancer Network : JN... Armstrong DK, Alvarez RD et. al.

Feb 6th, 2021 - Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the United States and is the country's fifth most common cause of cancer mortality in women. A major challenge in treating ovarian cancer is that most patients have...

SEOM clinical guideline in ovarian cancer (2020).
Clinical & Translational Oncology : Official Publication ... Redondo A, Guerra E et. al.

Jan 31st, 2021 - Despite remarkable advances in the knowledge of molecular biology and treatment, ovarian cancer remains the leading cause of death from gynecologic cancer. In the last decade, there have been important advances both in systemic and surgical treatm...

Breastfeeding Challenges: ACOG Committee Opinion, Number 820.
Obstetrics and Gynecology;

Jan 23rd, 2021 - Breastfeeding is associated with a decrease in a woman's risk of breast cancer, ovarian cancer, diabetes mellitus, and hypertensive heart disease. Breastfeeding initiation rates in the United States are increasing, and many women are aware of the ...

Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021,...
Journal of the National Comprehensive Cancer Network : JN... Daly MB, Pal T et. al.

Jan 7th, 2021 - The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic focus primarily on assessment of pathogenic or likely pathogenic variants associated with increased risk of breast, ovarian, and pancreatic cancer and r...

see more →

Drugs  83 results see all →

Clinicaltrials.gov  1,876 results

Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer

Jun 24th, 2022 - Background: Small cell lung cancer (SCLC) is an aggressive cancer with a poor prognosis. Although highly responsive to chemotherapy initially, SCLC relapses quickly and becomes refractory to treatment within a few months. Urothelial Carcinoma (UC)...

Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors

Jun 24th, 2022 - Background: Targeted therapies designed for specific genetic alterations, known as cancer driver mutations, have changed the treatment paradigm in advanced non-small cell lung carcinoma (NSCLC). Epidermal growth factor receptor (EGFR) tyrosine kin...

TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas

Jun 24th, 2022 - Background: -Base excision repair (BER) of DNA repair pathway has been implicated in resistance to both alkylating and antimetabolite chemotherapy. -TRC102 (methoxyamine HCl) acts through a novel mechanism to inhibit BER and has demonstrated the a...

Rapid Autopsy and Procurement of Cancer Tissue

Jun 24th, 2022 - Background: Despite being the leading cause of cancer-related death worldwide, there is only limited knowledge of tumor heterogeneity in lung cancer. There is also limited knowledge of tumor heterogeneity of other less common thoracic malignancies...

Prostate Lung Colorectal and Ovarian (PLCO) Cancer Screening Trial

Jun 24th, 2022 - The Division of Cancer Preventionl (DCP, formerly DCPC), under extramural contracts to 10 U.S. clinical centers, is evaluating the effectiveness of screening for prostate, lung, colorectal and ovarian cancer (The PLCO Trial). In 1996 the NCI Execu...

see more →

News  2,500 results

How to better identify and manage women with elevated breast cancer risk
MDedge Family Medicine; Sarina Schrager, MD, MS, Brenna Bomcamp, BS et. al.

Jun 13th, 2022 - Breast cancer is the most common invasive cancer in women in the United States; it is estimated that there will be 287,850 new cases of breast cancer in the United States during 2022 with 43,250 deaths. 1 Lives are extended and saved every day beca.

Which Malnutrition Criteria to Use in Gynecologic Cancers?

Jun 3rd, 2022 - Women with gynecologic cancers who meet criteria for malnutrition before surgery face a higher risk for poor postoperative outcomes. However, the value of preoperative malnutrition assessments depends on the definition of malnutrition used as well...

The perils of CA-125 as a diagnostic tool in patients with adnexal masses
Katherine Tucker, MD

May 24th, 2022 - CA-125, or cancer antigen 125, is an epitope (antigen) on the transmembrane glycoprotein MUC16, or mucin 16. This protein is expressed on the surface of tissue derived from embryonic coelomic and Müllerian epithelium including the reproductive tra.

Serum pepsinogen is associated with gastric cancer risk

May 23rd, 2022 - Key clinical point: Baseline serum pepsinogen levels are associated with a significant risk for gastric cancer, particularly the noncardia type. Major finding: A higher proportion of patients with gastric cancer vs matched controls had a positive.

Gynecologic Cancer Studies: What to Look for at ASCO 2022

May 20th, 2022 - This transcript has been edited for clarity. I'm Maurie Markman from Cancer Treatment Centers of America. I would like to briefly comment on the abstracts that have been released for the American Society of Clinical Oncology (ASCO) meeting coming ...

see more →

Patient Education  24 results see all →